Ticker Details
Acrivon Therapeutics, Inc.
IPO Date:	November 15, 2022
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$64.7M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.27 | 4.02%
Avg Daily Range (30 D):	$0.05 | 3.17%
Avg Daily Range (90 D):	$0.09 | 4.29%

Institutional Daily Volume
Avg Daily Volume:	.37M
Avg Daily Volume (30 D):	.56M
Avg Daily Volume (90 D):	1.17M

Trade Size
Avg Trade Size (Sh.):	156
Avg Trade Size (Sh.) (30 D):	219
Avg Trade Size (Sh.) (90 D):	189

Institutional Trades
Total Institutional Trades:	21
Avg Institutional Trade:	$2.21M
Avg Institutional Trade (30 D):	$.56M
Avg Institutional Trade (90 D):	$.56M
Avg Institutional Trade Volume:	.23M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.11M
Avg Closing Trade (30 D):	$1.11M
Avg Closing Trade (90 D):	$1.11M
Avg Closing Volume:	320.84K

News

Apr 17, 2026 @ 8:00 PM Acrivon to Highlight Preclinical Data with Three P... Source: Not Specified

Mar 17, 2026 @ 9:54 PM Acrivon Therapeutics to Present Pre-Clinical AP3 D... Source: Not Specified

Jul 15, 2025 @ 5:00 PM Endometrial Cancer Clinical Trial Pipeline Insight... Source: Delveinsight

Sep 14, 2024 @ 7:10 AM Acrivon Therapeutics Reports Positive Endometrial ... Source: N/A

Jul 10, 2024 @ 1:01 PM Athira (ATHA) Completes Dosing in Alzheimer's Stud... Source: N/A

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-2.02	$-.49	$-2.02
Diluted EPS	$-2.02	$-.49	$-2.02
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-77.91M	$-18.99M	$-77.91M
Operating Income / Loss	$-84.11M	$-20.12M	$-84.11M
Cost of Revenue
Net Cash Flow	$1.69M	$6.1M	$1.69M
PE Ratio